2019
DOI: 10.1093/ibd/izz247
|View full text |Cite
|
Sign up to set email alerts
|

Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis

Abstract: Background Improved treatment approaches for ulcerative colitis (UC), including novel medications, might reduce the need for colectomy. We performed a retrospective cohort study of adult patients (age 18–64) with UC in the United States to examine time trends for colectomy and biologic use from 2007 to 2016. Methods We estimated quarterly rates for colectomy and biologic use using the IQVIA Legacy PharMetrics Adjudicated Clai… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
36
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 39 publications
(41 citation statements)
references
References 40 publications
(38 reference statements)
3
36
0
Order By: Relevance
“…Recent evidence suggests that preoperative anti-TNF use may be an independent predictor of pouchitis. 30 Given that preoperative biologic use for UC will likely continue to increase 31 , 32 with the emergence of new mechanisms for the treatment of UC, we may see further increases in pouchitis and particularly chronic pouchitis in the near future. Currently there are no available results from randomized controlled trials evaluating the use of biologics in patients with pouch-related conditions.…”
Section: Discussionmentioning
confidence: 99%
“…Recent evidence suggests that preoperative anti-TNF use may be an independent predictor of pouchitis. 30 Given that preoperative biologic use for UC will likely continue to increase 31 , 32 with the emergence of new mechanisms for the treatment of UC, we may see further increases in pouchitis and particularly chronic pouchitis in the near future. Currently there are no available results from randomized controlled trials evaluating the use of biologics in patients with pouch-related conditions.…”
Section: Discussionmentioning
confidence: 99%
“…Biologics, such as anti‐TNFs and vedolizumab have dramatically changed the management of ulcerative colitis (UC) 1‐4 . However, these current therapies are limited by a lack of effectiveness, as only one‐third of treated patients achieves long‐term remission 5‐7 …”
Section: Introductionmentioning
confidence: 99%
“…Because of this, novel treatment options should be researched. In recent years, the use of biologics in UC patients has increased whereas colectomy rates have decreased [2,3]. However, many UC patients still have to undergo colectomy during their lifetime.…”
Section: Introductionmentioning
confidence: 99%